Apogee Therapeutics entered into a definitive merger agreement to be acquired by AbbVie, one of the world's leading biopharmaceutical corporations. This strategic acquisition brings Apogee's entire portfolio of advanced antibody assets under AbbVie's massive global commercial and clinical development infrastructure to expand its next-generation immunology franchise.